PARD3B

Across TCGA pan-cancer cohorts, PARD3B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PARD3B data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PARD3B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PARD3B expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where PARD3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.609	0.202	<.001	61	view →
CCRCC	DFS	Quartile	III,IV	1.000	0.607	.005	16	view →
LUAD	OS	Quartile	All	0.811	0.586	.038	4	view →
LSCC	DFS	Tertile	II,III,IV	0.788	1.000	.019	3	view →
UCEC	DFS	Tertile	All	0.940	0.805	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PARD3B–PDAC (DFS)

Open the PDAC breakdown →